Effect of Endogenous Opioid Peptides on
The present experiments show the presence of both metenkephalin-like and met-enkephalin-Args-Phe7-like immunoreactivity in the superior cervical ganglion of the cat; this was determined by radioimmunoassay after high-pressure liquid chromatography separation of tissue extracts. There was measurable efflux of both peptides, as determined by radioimmunoassay of ganglionic perfusates; this measure was increased by thiorphan, an enkephalinase inhibitor. The effect of the 2 peptides on ACh release was determined: The stable analog of methionine-enkephalin, D-Ala2-methionine-enkephalinamide, did not affect ACh release from the ganglion; in contrast, methionine-enkephalin-Args-Phe7 significantly depressed evoked ACh release. The effect of met-enkephalin-Args-Phe7 to decrease ACh release was antagonized, although only partially, by the opioid antagonist naloxone. Thus, it appears that methionine-enkephalin-ArgsPhe7 alters ACh release from the superior cervical ganglion by acting, at least in part, on a presynaptic opioid receptor. The results suggest that in the cat superior cervical ganglion, the heptapeptide enkephalin might have a significant role in the regulation of synaptic transmission, which is unrelated to its potential function as a precursor for methionine-enkephalin.
There is now considerable evidence supporting the idea that neuropeptides coexist with conventional transmitter substances in the nervous system (see, for example, Schultzberg et al., 1978a Schultzberg et al., , b, 1979 Schultzberg, 1984) . The functional significance of this colocalization is not always clear, but it is usually considered that the peptide might interact presynaptically or postsynaptitally to modify the release or the action of the classical transmitter.
The presence of opioid peptides and precursors has been demonstrated in sympathetic ganglia. Thus, met-enkephalin-like (ME-like) immunoreactivity is evident by histochemical (Schultzberg et al., 1979; Dalsgaard et al., 1982) or radioimmunoassay (DiGiulio et al., 1978 (DiGiulio et al., , 1979 techniques; and metenkephalin-Arg6-Phe' (MEAP), the carboxyl terminal heptapeptide of preproenkephalin A (Comb et al., 1982; Gubler et al., 1982; Noda et al., 1982) , is demonstrable by immunohistochemistry (Tang et al., 1982 (Tang et al., , 1983 Helen et al., 1984) .
In certain autonomic ganglia, such as the inferior mesenteric and superior-celiac ganglia of the guinea pig (Konishi et al., 1979, 198 1) and the superior cervical ganglion of rat and rabbit (Dun and Karczmar, 198 l) , met-enkephalin appears to act presynaptically to reduce ACh release (for review, see Dun, 1983) . The effect of MEAP upon transmission at autonomic ganglia has not been studied, although at some neuroeffector sites, such as cholinergic synapses in the guinea pig ileum and adrenergic synapses in the mouse vas deferens, MEAP acts like ME to reduce transmitter release Rossier et al., 1980; H&-sing et al., 1984) .
The present experiments were undertaken to measure the effect of ME and MEAP on ACh release from the cat superior cervical ganglion. The results show that these 2 peptides are present in measurable quantities in this tissue and that they differ in their ability to affect ACh release from preganglionic nerve terminals.
Materials and Methods
Materials.
[+*P]ATP (2-10 Ci/mmol) and Aquasol were purchased 1.2; MgSO, .7H,O, 1.2; glucose, 9.8; and NaHCO,, 25; this was equilibrated with 5% CO, in 0, to maintain a pH of 7.4 at 37°C. In all cases, the perfusion medium contained choline chloride ( 1O-5 M) to support ACh synthesis and physostigmine sulfate (1.5 x 1O-5 M) to allow collection of released ACh; as specified in the text, one or more of the following was added: MEAP, DAEA, MEAGL, thiorphan, and naloxone hydrochloride.
The preganglionic nerve was cut low in the neck and was stimulated with square-wave pulses (8 V, 0.3 msec) delivered through platinum electrodes. Each stimulation period was 2 min long, and the frequency of stimulation was 20 Hz.
In experiments that measured ACh release, ganglia were perfused with Krebs solution containing choline and physostigmine for at least 10 min before collecting samples for assay. Then, ganglionic effluents were collected as 2 min samples: a 2 min collection with the ganglion at rest was followed by a 2 min collection during which the ganglion was stimulated via the preganglionic sympathetic nerve. Each period of stimulation was separated from the next by a 6 min rest period. When switching from one perfusion medium to another, there was a 10 min washout period before collection of the next test samples. Evolded ACh release represents the ACh released during the 2 min period of stimulation minus the ACh released during the preceding 2 min rest period. In each experiment, under each condition, 2 such tests were made and the value for evoked release was calculated as the average.
Assay for ACh. The ACh content of ganglionic effluents was determined by the radioenzymic assay of Goldberg and McCaman (1973) as described by Kwok and Collier (1982) . ACh was extracted from ganglionic effluents by tetraphenylboron/heptanone (10 mg/ml) and recovered from the organic phase by shaking with a half volume of AgNO, (0.12 M) as described by Fonnum ( 1969) . Excess silver was precipitated by addition of 10 ~1 of MgCl, (1 M) per 100 ~1 sample. Samples were then lyophilized and redissolved in 32 ~1 of a reaction medium containing ATP (0.8 mM), dithiothreitol(5 mM), MgCl, (12.5 mM), glycylglycine (25 mM, pH 8.3), and choline kinase (0.005 U). These samples were incubated at 30°C for 30 min to phosphorylate any endogenous choline in the samples. A solution (10 ~1) containing AChE (2 U) and 'lP-ATP (approximately 0.45 PCi) was added to each sample, which was then reincubated for 25 min at 30°C. During this second incubation, sample ACh was hydrolyzed and the choline thus formed was phosphorylated to 3*P-phosphorycholine. After the reaction was terminated by the addition of 100 pl ice-cold NaOH (50 mM), radioactive phosphorylcholine was separated from unchanged 32P-ATP by ion-exchange chromatography on Amberlite CG-400 (converted to formate form) columns, which had been previously equilibrated with NaOH (50 mM). Phosphorylcholine was eluted with 3 ml of NaOH (50 mM). For each experiment, standard amounts of ACh dissolved in Krebs medium of the same composition as the samples were extracted and assayed along with the test samples.
Assay for enkephalin-like immunoreactivity. Ganglia were extracted with 0.1 M acetic acid, usually containing 10m4 M PCMS, to prevent peptide breakdown in vitro; these extracts were neutralized with 1 M sodium hydroxide. Aliquots of ganglionic extracts were lyophilized and peptide content was determined by a radioimmunoassay, using antibodies to ME. The ME antibody used in the assay exhibited >70% and > 50% cross-reactivity with MEAP and MEAGL, respectively, but crossreacted less than 20% with LE. On HPLC. both leu-enkenhalin and MEAGL elute in different fractions from ME and MEAP and can therefore be separated from ME and MEAP. The antibody has also been tested for cross-reactivity with the following: substance P, /3-endorphin, a-neoendorphin, and dynorphin( l-l 3); in all cases, the cross-reactivity was < 1%. For determination of enkephalin content of ganglionic perfusates, aliquots of effluents were lyophilized and assayed with the radioimmunoassay described above. For HPLC separation of peptides, samples were first resuspended in 0.1% TFA in 25% acetonitrile and subiected to reverse-nhase HPLC on a C,, p-Bondapak column (3.9 mm x 30 cm), which was connected to a Guard-PAK precolumn fitted with a C,, insert. Samples were injected into a U6K manual injector. The solvent delivery system consisted of dual model 5 10 pumps; the pumping rate (1 .O ml/min) was regulated by a Waters automated gradient controller. The mobile phase through the column consisted of 0.1% TFA (O-10 min); peptides were then eluted, as described by Hersh (1984) with 0.1% TFA in an acetonitrile gradient (O-60% in 20 min). Absorbance, at 214 nm, was detected by a Lambda-Max model 481 LC spectrophotometer and recorded by a 740 Data Module. Fractions were collected using a 2 112 Redirac Collector (LKB, Bromma, Sweden), with a lag time of approximately 0.2 min compared to the chromatogram, at 1 or 2 min intervals, lyophilized, and assayed for peptide content as described above. Standard amounts (0.05 mg) of peptides eluted on HPLC with the following average retention times: 26.7,28.9,28.0, and 27.3 min for ME, MEAP, MEAGL, and LE, respectively.
The peptides (DAEA, MEAP, and MEAGL) used for testing the effect of ACh released from the perfused cat superior cervical ganglion were 97% pure as determined bv HPLC analvsis.
Determination of radioactivity. 12P was determined with approximately 100% efficiency by liquid scintillation spectrometry (LKB) using Aquasol as the solvent system. lzsI was counted with 590% efficiency in a gamma-counter.
Results

Enkephalin content of ganglia
To test whether enkephalin was present in the superior cervical ganglion of the cat, ganglia were extracted in 0.1 M acetic acid Figure 2 . ME and MEAP content of the cat superior cervical ganglion. Ganglia were extracted in acid-containing PCMS (10 + M); extracts were then subjected to reverse-phase HPLC prior to radioimmunoassay. Enkephalin-like immunoreactive material was measured in the 2 fractions shown in Figure 1 , one corresponding to ME and the other to MEAP. Results represent the mean * SEM of 5 experiments.
and enkephalin-like immunoreactivity was determined by radioimmunoassay, using antibodies against ME. In some cases, extraction was in the presence of PCMS (1 O-4 M) or of bacitracin (2 x 1O-5 M). The results showed measurable enkephalin-like immunoreactivity in ganglion extracts (see Table 1 ); recovery of enkephalin-like immunoreactivity from extracts was enhanced when PCMS, but not bacitracin, was added to the extraction medium, indicating that the former, but not the latter, can prevent enzymatic degradation of enkephalins by this tissue in vitro.
Recovery of enkephalin-like immunoreactivity from ganglia was enhanced when acid extracts were first subjected to reversephase HPLC prior to radioimmunoassay. In these experiments, ganglia were extracted with acetic acid and PCMS. Assay of samples after HPLC yielded a value for total immunoreactive enkephalin of 2209 f 5 13 pg/ganglion, about 75% more than was measured by radioimmunoassay alone. More importantly, this enkephalin-like immunoreactivity was recovered in 2 separate fractions from HPLC (Fig. 1A) . Enkephalin-like immunoreactivity in the first fraction eluted with a retention time that corresponded to a standard of ME (Fig. lB) , and immunoreactivity in the second fraction corresponded to a standard of MEAP (Fig. 1B) . The 2 "peaks" of immunoreactive material were clearly distinct (Fig. 1) . Immunoreactivity in "peak 2" was recovered in 2 consecutive fractions: This might be the result of the broad resolution on HPLC of the heptapeptide (Fig. lB) , such that elution occurs over 2 fractions.
As mentioned in Materials and Methods, the antibody used in the radioimmunoassay partly cross-reacted with LE and MEAGL, and attention was given to these 2 peptides. Both LE and MEAGL would be expected to elute in the 27-28 min fraction, but there was no peak corresponding to LE or MEAGL in this fraction (Fig. 1) . However, the possibility that a part of the second "peak" was MEAGL cannot be completely eliminated. If one takes into account the lag time (0.2 min) between the chromatogram and collection of fractions, the retention time of MEAGL, and the sharp resolution on HPLC of the octapeptide, it is likely that most of the MEAGL-like immunoreactivity elutes in the fraction between "peak 1" and "peak 2" and that only a small amount elutes in "peak 2" (Fig. 1A) .
The results of 5 experiments are summarized by Fig. 2 : 66.2 + 11.6% ofthe enkephalin-like material corn&rated on HPLC with authentic ME and 33.1 f 13.4% with MEAP (Fig. 2) . 
Eflux of ME and MEAP from ganglia
In 7 experiments, ganglia were perfused with Krebs medium and effluent was collected for radioimmunoassay. There was measurable immunoreactivity in perfusates, and this was increased in the presence of thiorphan (Fig. 3) . By HPLC, the immunoassayable activity of ganglionic effluents was separated into 2 peaks: one co-eluted with ME and represented 84.5 f 11% (n = 5) of the total immunoreactivity; the other (15.5 f 7%) corresponded to MEAP. A few experiments tested whether preganglionic stimulation (20 Hz) altered efflux of enkephalinlike immunoreactivity; the test was negative.
Effects of exogenous ME on ACh release from ganglia
To test whether exogenous ME affects ACh release, ganglia were perfused with a stable analog of methionine-enkephalin, DAEA. Ganglia were first perfused with normal Krebs medium and evoked ACh release during preganglionic stimulation at 20 Hz was measured. Then, ganglia were perfused with DAEA in a cumulative-concentration schedule (1 O-9-1 O-5 M), and ACh release was determined for each concentration of peptide. As shown in Figure 4 , DAEA had little or no effect on evoked ACh release. A higher concentration (1 O-4 M) of DAEA similarly did not alter evoked ACh release from ganglia: Release in the presence of DAEA was 110 f 19% of that in its absence.
Studies on the central effects of DAEA have shown that the analgesia produced by intracerebroventricular injection of this analog can be potentiated by inhibitors of "enkephalinase" (Algeri et al., 1981; Chipkin et al., 1982) , suggesting that DAEA might be subject to "enkephalinase" degradation. Thus, in other experiments, we tested whether thiorphan, an enkephalinase inhibitor (Rogues et al., 1980; Schwartz et al., 1981; Schwartz, 1983) , enhanced the effect of DAEA. The test was negative: In the presence of thiorphan ( 1O-4 M), DAEA appeared to depress evoked ACh release modestly (85 f 15%), but this depression was not more than that seen with thiorphan (85 f 9%) alone.
Spontaneous ACh release from ganglia was not significantly affected by DAEA: Release in the presence of the analog ranged from 6.3 f 1.2 (1O-9 M) to 7.1 rf: 3.2 pmol/min (1O-4 M), compared to 5.0 + 0.9 pmol/min in its absence.
Eflects of exogenous MEAP on ACh release
The purpose of these experiments was to test whether MEAP can effect ACh release. Ganglia were first perfused with normal Krebs solution and ACh release during preganglionic stimulation (20 Hz) was evaluated; then, ganglia were perfused with increasing concentrations of MEAP (10-9-10-6 M), and ACh release was again measured for each concentration of peptide. In contrast to the ME analog, MEAP significantly depressed evoked ACh release at all concentrations tested (Fig. 5, closed  symbols) .
To determine whether this depression of ACh release was due to an action on presynaptic opioid receptors, the opioid receptor antagonist naloxone was tested for its ability to antagonize the MEAP effect. In this experiment, ganglia were perfused with increasing concentrations of MEAP in the presence of naloxone ( 10m6 M) and the result compared to the above series in the absence of naloxone. MEAP appeared to be less effective in depressing evoked ACh release in the presence of naloxone (Fig.  5, open symbols) . Naloxone alone had no significant effect on evoked ACh release from ganglia (Fig. 5) .
Other experiments confirmed that MEAP decreased ACh release and tested the reversal of this effect by naloxone at varying concentrations. For this test, each ganglion was perfused first without drug, then with MEAP (lo-' M), and then with MEAP together with naloxone (see Fig. 6 ). At a concentration of 1O-6 M, naloxone partially reversed the MEAP-induced inhibition of evoked ACh release (Fig. 6~) ; this antagonism was not significantly enhanced by increasing the concentration of naloxone to 10~~ M (Fig. 6b) or to 5 x lop5 M (Fig. 6~) . At these higher concentrations of antagonist, naloxone itself appeared to depress evoked ACh release (Fig. 6,b,c) .
Spontaneous ACh release was not significantly affected by either naloxone or MEAP or their combination ( Table 2) .
Effect of exogenous MEAGL on ACh release Because HPLC of ganglion extracts did not entirely eliminate the possibility that MEAGL contributed to endogenous opioid peptides measured, we tested its effect on ACh release from the cat superior cervical ganglion. Ganglia were first perfused with normal Krebs medium, following which they were perfused with increasing concentrations ( 10-9-10-7 M) ofthe octapeptide. Unlike the heptapeptide MEAP, MEAGL did not significantly affect evoked ACh release: Release in the presence of 1O-g, IO-*, and lo-' M MEAGL was 98 f 2,93 + 5, and 90 f 7% of that in its absence, respectively. Thus, MEAGL is similar to ME in this respect. In addition, the peptide did not alter spontaneous ACh release from the ganglion: Release in the presence of peptide ranged from 6.5 f 1.1 (10~~ M) to 8.9 -t 2.3 (1O-7 M) pmol/ min compared to 4.7 f 2.2 pmol/min in its absence.
Discussion
The present study was undertaken to determine if enkephalins can alter ACh release in the cat superior cervical ganglion. First, we measured the content of and efflux of endogenous enkephalins in this ganglion; second, we tested the effect of exogenous enkephalins on ACh release; third, we determined if this effect was the result of activation of presynaptic opioid receptors, that is, if it was naloxone-sensitive. Endogenous opioid pentapeptides were first identified in brain extracts (Hughes et al., 1975) . Since then, various peptides with opioid activity, including the heptapeptide and octapeptide enkephalins, have been found in brain and other tissues. The heptapeptide MEAP was initially purified from bovine adrenal extracts (Stem et al., 1979) and shortly thereafter from brain extracts of several species . MEAP has also been detected in sympathetic ganglia, perhaps coexisting with the pentapeptide ME (Tanget al., 1982; Helen et al., 1984; Wang et al., 1984 ; see also Panula et al., 1984) . In these ganglia, ME has been shown to be localized in preganglionic nerve fibers, in small intensely fluorescent cells, and in catecholamine-containing principal ganglion cells (DiGiulio et al., 1978; Schultzberg et al., 1979) . In contrast, MEAP has been identified as yet only in preganglionic nerve fibers (see Helen et al., 1984) . The present results demonstrate that both the penta-and heptapeptide enkephalins, ME and MEAP, appear to be present in the cat superior cervical ganglion, and in this respect it resembles other sympathetic ganglia (see above). Furthermore, the present experiments measured an efflux of both ME and MEAP into perfusate collected from the perfused ganglion preparation. This would be evident at the cholinergic synapse nor what factors might change such a concentration; in the present experiments, preganglionic stimulation at 20 Hz did not alter ME efflux, although it remains possible that other stimulation parameters would.
The main objective of this study was to test whether enkephalins-which, as shown by our results, are present in the cat superior cervical ganglion-have any effect on ACh release. To this end, we tested the effects of exogenous penta-, hepta-, and octapeptide on spontaneous and evoked ACh release from the cat superior cervical ganglion. The stable analog of ME, DAEA, had little or no effect on ACh release from the perfused superior cervical ganglion of the cat. This contrasts with the findings of Konishi and coworkers (1979) who showed that in the guinea pig, DAEA depressed EPSPs in the inferior mesenteric and celiac-superior ganglion by presynaptic inhibition of ACh release. Similar results were obtained for the superior cervical ganglion of rat and rabbit (Dun and Karczmar, 1981) , where both metand leu-enkephalin depressed EPSPs by reducing ACh release from presynaptic nerve terminals. The reason for the different results obtained in the present study is not clear: It could reflect different mechanisms of regulation of ACh release between species, or between perfused and isolated preparations, or it could be the result of differences in parameters of stimulation.
Unlike ME, MEAP significantly depressed evoked ACh release. This effect of MEAP was concentration dependent and was partially reversed by naloxone. Although it is known that MEAP can be metabolized in vitro by a dipeptidyl carboxypep- 10-g 10-G 6.5 + 2.1 10-x 10-e 5.9 T.k 1.1 10-7
10-e 6.3 f 1.5 10-G 10-G 7.2 + 1.9
The results are expressed as the mean k SEM of 4 experiments in each set (A and B). Release in the presence of MEAP or naloxone or both is not significantly different from that in their absence (-) @ > 0.05).
tidase (see Yang et al., 198 1; Lindberg et al., 1982a, b; Hersh, 1984) thereby releasing ME, the effects of the heptapeptide in the present experiments are unlikely to be the result of this, since DAEA was shown to have no effect on ACh release. Therefore, in the cat superior cervical ganglion, it appears that MEAP might be processed from its precursor and function as an opioid agonist in its own right. Several findings, including the results reported here, support the hypothesis that MEAP is not only an intermediate in the synthesis of ME. First, the distribution of the 2 peptides is not always parallel (Tang et al., 1982; Dockray, 1982, 1983) . Second, MEAP has been shown to be released in a calcium-dependent manner by high K+ from rat and guinea pig lung slices (Tang et al., 1983) and from rat striatal slices (Patey et al., 1985) . Third, the heptapeptide was shown to be more potent than the pentapeptide in the following tests: inhibition of the electrically induced twitch of the guinea pig ileum , analgesia induced by intracerebroventricular administration to mice (Inturrisi et al., 1980) , and inhibition of ACh-induced catecholamine secretion from chromaffin cells in culture (Saiani and Guidotti, 1982) .
The results of our study show that the effect of MEAP in depressing evoked ACh release from the ganglion is only partially antagonized by naloxone. The reason for this partial reversal is not clear. It is possible that part of the effect of MEAP on ACh release is mediated by nonopiate metabolites such as Arg-Phe or Phe-Met-Arg-Phe, which are known, for example, to have cardiovascular effects (for a review, see Holaday, 1983) . Alternatively, it may be that at least part of the action of the heptapeptide is mediated by a nonopioid receptor or by an opioid receptor that is relatively insensitive to naloxone, that is, not of either the mu-or delta-receptor subtype. This suggestion is supported by the insensitivity of ACh release to morphine (see Macintosh and Collier, 1976 ) a mu-opiate receptor agonist, and to ME (present results), a delta-opiate receptor agonist. Saiani and Guidotti (1982) reported that cultured chromaffin cells bind MEAP with high affinity to an opiate receptor that
